B-ALL Trial Report | Venetoclax + Anti-CD20? | AML Posttransplantation MRD MonitoringMay 26, 2021 | Oncology Hematology Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL In this Original Report from the Journal of Clinical Oncology, the authors conducted a phase I trial of autologous CD19 CAR T cells in children and young adults (CAYAs) with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) to discover whether the role for allogeneic hematopoietic stem-cell transplant (alloHSCT) following CD19-CAR T-cell therapy can improve long-term outcomes. Read full article Hematology Should Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL? In this interview with Dr. Richard Furman, Professor of Medicine at New York-Presbyterian Weill Cornell Medicine, the importance of the CLL14 study is highlighted. In addition, Dr. Furman discusses the best use of venetoclax and whether anti-CD20 agents really add to the benefit of venetoclax treatment and whether a policy of watch and wait is still beneficial for all patients. Read full article Hematology Posttransplantation MRD Monitoring in Patients w. AML by Next-Generation Sequencing Using DTA and Non-DTA Mutations In this article from Blood Advances highlighted by helpful visual abstracts, two key points are discussed. First, patient-specific next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring using non-DTA mutations after allogeneic hematopoietic cell transplantation (alloHCT) is independently prognostic for relapse and survival. Second, the kinetics rather than a single time point should be further evaluated when DTA mutations are used for MRD monitoring after alloHCT. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS